53 related articles for article (PubMed ID: 2803945)
1. Mechanisms of amine accumulation in, and egress from, lysosomes.
Goldman SD; Funk RS; Rajewski RA; Krise JP
Bioanalysis; 2009 Nov; 1(8):1445-59. PubMed ID: 21083094
[TBL] [Abstract][Full Text] [Related]
2. A cell fractionation approach for the quantitative analysis of subcellular drug disposition.
Duvvuri M; Feng W; Mathis A; Krise JP
Pharm Res; 2004 Jan; 21(1):26-32. PubMed ID: 14984254
[TBL] [Abstract][Full Text] [Related]
3. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Lehne G; De Angelis P; Clausen OP; Rugstad HE
Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
[TBL] [Abstract][Full Text] [Related]
4. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
Warrell RP
Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
[TBL] [Abstract][Full Text] [Related]
5. Resistance to multiple chemotherapeutic agents in human cancer cells.
Gottesman MM; Pastan I
Trends Pharmacol Sci; 1988 Feb; 9(2):54-8. PubMed ID: 3072730
[No Abstract] [Full Text] [Related]
6. Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
Millot JM; Rasoanaivo TD; Morjani H; Manfait M
Br J Cancer; 1989 Nov; 60(5):678-84. PubMed ID: 2803945
[TBL] [Abstract][Full Text] [Related]
7. Effect of aclacinomycin-doxorubicin association on differentiation and growth of human erythroleukemic K562 cells.
Nyoung MN; Trentesaux C; Aries A; Carpentier Y; Jardillier JC; Gorisse MC; Jeannesson P
Anticancer Res; 1994; 14(3A):1203-8. PubMed ID: 8074473
[TBL] [Abstract][Full Text] [Related]
8. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
Sebille S; Morjani H; Poullain MG; Manfait M
Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
[TBL] [Abstract][Full Text] [Related]
9. Correlation between growth inhibition and intranuclear doxorubicin and 4'-deoxy-4'-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry.
Gigli M; Rasoanaivo TW; Millot JM; Jeannesson P; Rizzo V; Jardillier JC; Arcamone F; Manfait M
Cancer Res; 1989 Feb; 49(3):560-4. PubMed ID: 2910478
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
11. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
12. The interaction of daunorubicin and doxorubicin with DNA and chromatin.
Zunino F; Di Marco A; Zaccara A; Gambetta RA
Biochim Biophys Acta; 1980 Apr; 607(2):206-14. PubMed ID: 7370266
[TBL] [Abstract][Full Text] [Related]
13. Interaction of adriamycin with DNA as studied by resonance Raman spectroscopy.
Manfait M; Alix AJ; Jeannesson P; Jardillier JC; Theophanides T
Nucleic Acids Res; 1982 Jun; 10(12):3803-16. PubMed ID: 7111023
[TBL] [Abstract][Full Text] [Related]
14. Plasma kinetics of aclacinomycin A and its major metabolites in man.
Egorin MJ; Van Echo D; Fox BM; Whitacre M; Bachur NR
Cancer Chemother Pharmacol; 1982; 8(1):41-6. PubMed ID: 6954015
[TBL] [Abstract][Full Text] [Related]
15. High performance liquid chromatographic determination of aclacinomycin a and its related compounds. II. Reverse phase HPLC determination of aclacinomycin A and its metabolites in biological fluids using fluorescence detection.
Ogasawara T; Masuda Y; Goto S; Mori S; Oki T
J Antibiot (Tokyo); 1981 Jan; 34(1):52-7. PubMed ID: 6941958
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
